The KRASG12C inhibitors in lung cancer therapy

• Egile Nagusiak: Maciej Jędrak (Egilea), Karolina Niekurzak (Egilea), Joanna Kania (Egilea), Maciej Józefiak (Egilea), Piotr Sobkiewicz (Egilea), Krzysztof Kania (Egilea)
• Formatua: Liburua
• Argitaratua: Kazimierz Wielki University, 2023-09-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Introduction: Lung cancer is characterized by the highest mortality among cancers and is the second most frequently diagnosed type of cancer in the world. Targeted therapies are a promising therapeutic option for patients with this disease, however, one of the most common and most malignant mutation...